http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-041302-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2003-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-041302-A1 |
| titleOfInvention | IMIDAZOPIRIDINE COMPOUNDS AS RECEIVER AGONISTS 5- HT4 AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH COMPOUNDS |
| abstract | Imidazopyridine compounds with agonist binding activity to the 5-HT4 receptor and thus are useful for the treatment or prevention of diseases such as esophageal reflux; gastrointestinal disease, gastric motility disorders, non-ulcer dyspepsia and functional dyspepsia; diseases of the central nervous system; Alzheimer disease; cardiovascular disorder or similar in mammals, especially in humans. It also comprises a pharmaceutical composition that includes the preceding compounds. Claim 1: A compound of formula (1), characterized in that: R1 represents a hydrogen atom or a halogen atom; R2 represents a methyl group or an ethyl group; R3 represents a C3-6 branched alkyl group or a C3-6 alkyl group substituted by a C1-6 alkoxy group; with the proviso that when the terminal carbon atom of said alkyl group is replaced by said alkoxy group, said alkyl group is a branched alkyl group; Pharmaceutically acceptable salts thereof. Claim 14: The use of a compound according to claim 13, characterized in that said condition is esophageal reflux disease, gastrointestinal disease, gastric motility disorder, small intestine motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome, constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, ischemic stroke, anxiety or cardiovascular disorder. |
| priorityDate | 2002-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.